Health
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers – StreetInsider.com
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer,…
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is…
-
Business23 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News22 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General17 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News19 hours agoTips to improve engagement – Proctor